<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02726386</url>
  </required_header>
  <id_info>
    <org_study_id>ND0612H-012</org_study_id>
    <nct_id>NCT02726386</nct_id>
  </id_info>
  <brief_title>A Clinical Study Investigating Long Term Safety of ND0612, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease</brief_title>
  <official_title>A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroDerm Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroDerm Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, international, open-label, safety study of ND0612, a solution of
      levodopa/carbidopa (LD/CD) delivered via a pump system as a continuous SC infusion in
      subjects with advanced Parkinson's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase open-label safety study will be conducted in approximately 100 subjects.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the long term safety (systemic and local) and tolerability of continuous subcutaneous infusion of ND0612 by adverse events, vital signs, local tolerability</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>ND0612 (Levodopa/Carbidopa solution) - Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen 1 of ND0612 (LD/CD solution) continuous subcutaneous infusion over 24 hrs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ND0612 (Levodopa/Carbidopa solution) - Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen 2 of ND0612 (LD/CD solution) continuous subcutaneous for over 14-16 hrs .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ND0612</intervention_name>
    <description>ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system</description>
    <arm_group_label>ND0612 (Levodopa/Carbidopa solution) - Regimen 1</arm_group_label>
    <arm_group_label>ND0612 (Levodopa/Carbidopa solution) - Regimen 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female ,Parkinson's disease subjects of any race aged 30 to 85 years .

          -  PD diagnosis consistent with the UK Brain Bank Criteria.

          -  Modified Hoehn &amp; Yahr scale in &quot;ON&quot; state of stage ≤3.

          -  Taking at least 4 doses/day of Levodopa (or at least 3 doses/day of Rytary) and
             taking, or have attempted to take, at least 1 other Parkinson's disease treatment for
             at least 30 days in the previous year.

          -  Subjects must be stable on their anti-Parkinson's disease medications for at least 30
             days before Day 1.

          -  Subjects may have had prior exposure to Sub Cutaneous apomorphine injections/infusion
             but must have stopped administration at least 4 weeks before the screening visit.
             Treatment with apomorphine is prohibited during the entire ND0612 treatment period.

          -  Must have a minimum of 2 hours of &quot;OFF&quot; time per day with predictable early morning
             &quot;OFF&quot; periods as estimated by the subject.

          -  Must have predictable and well defined early morning &quot;OFF&quot; periods with a good
             response to Levodopa for treatment of the early morning &quot;OFF&quot; in the judgement of the
             investigator.

          -  Mini Mental State Examination (MMSE) score &gt;26.

          -  No clinically significant medical, psychiatric or laboratory abnormalities which the
             investigator judges would be unsafe or non-compliant in the study.

          -  Female subjects must be surgically sterile (hysterectomy, bilateral oophorectomy, or
             tubal ligation), postmenopausal (defined as cessation of menses for at least 1 year),
             or willing to practice a highly effective method of contraception. All female
             participants must be non-lactating and non-pregnant and have a negative urine
             pregnancy test at Screening and at Baseline. Female subjects of childbearing potential
             must practice a highly effective method of contraception ( oral contraceptives plus a
             barrier method of birth control [condoms with contraceptive foams, diaphragms with
             contraceptive jelly], intrauterine devices, partner with vasectomy), 1 month before
             enrollment, for the duration of the study, and 3 months after the last dose of study
             drug.

          -  Willing and able to administer the subcutaneous infusion alone or with the assistance
             of a study partner after a screening period of 28 days and willing and able to comply
             with study requirements.

        Exclusion Criteria:

        For Cohort 1 and Cohort 2, the following exclusion criterion applies:

          -  Previously unable to tolerate ND0612 and/or have experienced intolerable adverse drug
             reactions associated with its use, regardless of the dosing regimen administered.

        For Cohort 2, the following exclusion criteria apply:

          -  Atypical or secondary parkinsonism.

          -  Acute psychosis or hallucinations in past 6 months.

          -  Any relevant medical, surgical, or psychiatric condition, laboratory value, or
             concomitant medication which, in the opinion of the Investigator makes the subject
             unsuitable for study entry or potentially unable to complete all aspects of the study.

          -  Prior neurosurgical procedure for Parkinson's disease, or duodopa treatment.

          -  Subjects with a history of drug abuse or alcoholism within the past 12 months.

          -  Clinically significant ECG rhythm abnormalities.

          -  Renal or liver dysfunction that may alter drug metabolism including: serum creatinine
             &gt;1.3 mg/dL, serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT)
             &gt;2 x upper limit of normal (ULN), total serum bilirubin &gt;2.5 mg/dL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xenoscience</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205-6421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Parkinsons and Movement Disorder Institute</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708-5153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro Pain Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113-2776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorder Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486-2359</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research, LLC</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health at Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, PA</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751-4723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinsons Disease Treatment Center of Southwest Florida</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Neuroscience Associates</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713-8844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research, LLC</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USF Health Parkinson's Disease and Movement Disorders</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unity Point Health</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Neurology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QUEST Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pyramid Clinical Research</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>08873-3448</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Movement Disorder Clinic of Oklahoma</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Trials</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Neuroscience Institute</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456-0168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202-1461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEUROHK, s.r.o.</name>
      <address>
        <city>Chocen</city>
        <zip>565 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clintrial s.r.o.</name>
      <address>
        <city>Praha</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vestra Clinics, s.r.o.</name>
      <address>
        <city>Rychnov nad Kněžnou</city>
        <zip>516 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Aix</name>
      <address>
        <city>Aix-en-Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens, Hopital Sud</name>
      <address>
        <city>Amiens Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Neurologique Pierre Wertheimer</name>
      <address>
        <city>BRON Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand Cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Beelitz GmbH</name>
      <address>
        <city>Beelitz-Heilstätten</city>
        <zip>14547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josefs Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum-Bremerhaven Reinkenheide</name>
      <address>
        <city>Bremerhaven</city>
        <zip>27574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Haag</name>
      <address>
        <city>Haag in Oberbayern</city>
        <zip>83527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-und Rehabilitationskliniken Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai MC</name>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center, Ein-Kerem Campus</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>56520</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Foundation</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele Pisana</name>
      <address>
        <city>Rome</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Hospital San Camillo Venice</name>
      <address>
        <city>Venice</city>
        <zip>30126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne PLEJADY</name>
      <address>
        <city>Kraków</city>
        <zip>30-363</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowska Akademia Neurologii Sp. z o.o.</name>
      <address>
        <city>Kraków</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Praktyka Lekarska prof. dr hab</name>
      <address>
        <city>Lublin</city>
        <zip>20-016</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2016</study_first_posted>
  <last_update_submitted>December 26, 2017</last_update_submitted>
  <last_update_submitted_qc>December 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

